![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/en/news-release/2024/07/09/2910278/0/en/Reviva-Announces-Grant-of-European-Patent-Covering-Use-of-Brilaroxazine-for-the-Treatment-of-Pulmonary-Hypertension.html
https://www.globenewswire.com/news-release/2024/05/29/2890315/0/en/Reviva-Announces-Closing-of-3-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html
https://www.globenewswire.com/news-release/2024/05/28/2888989/0/en/Reviva-Announces-3-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html
https://www.globenewswire.com/news-release/2024/05/21/2885506/0/en/Reviva-to-Participate-in-the-BIO-International-Convention.html
https://www.globenewswire.com/news-release/2024/05/15/2882369/0/en/Reviva-Announces-Enrollment-Update-for-Open-Label-Extension-Study-Evaluating-Brilaroxazine-in-Schizophrenia.html
https://www.globenewswire.com/news-release/2024/05/14/2881334/0/en/Reviva-Reports-First-Quarter-2024-Financial-Results-and-Recent-Business-Highlights.html
https://www.globenewswire.com/news-release/2024/05/13/2880357/0/en/Reviva-to-Present-New-Preclinical-Efficacy-Data-on-Brilaroxazine-in-Idiopathic-Pulmonary-Fibrosis-at-2024-ATS-International-Conference.html
https://www.globenewswire.com/news-release/2024/05/09/2878710/0/en/Reviva-to-Present-New-Non-Clinical-Pharmacology-Data-on-Brilaroxazine-at-the-ASPET-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/04/15/2862741/0/en/Reviva-Reports-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights.html
https://www.globenewswire.com/news-release/2024/03/28/2853940/0/en/Reviva-to-Present-RECOVER-Phase-3-Clinical-Trial-Data-for-Brilaroxazine-in-Schizophrenia-at-the-SIRS-2024-Annual-Meeting.html